The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGINV.L Regulatory News (GINV)

  • There is currently no data for GINV

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Response to Full Year Results Queries from SGX-ST

14 Mar 2023 09:30

RNS Number : 8925S
Global Invacom Group Limited
14 March 2023
 

 

 

 

GLOBAL INVACOM GROUP LIMITED

(Incorporated in the Republic of Singapore)

(Company Registration No. 200202428H)

 

 

RESPONSE TO QUERIES FROM SINGAPORE EXCHANGE SECURITIES TRADING LIMITED ("SGX-ST") ON THE FULL YEAR RESULTS FOR FY2022

 

 

The Board of Directors (the "Board") of GLOBAL INVACOM GROUP LIMITED (the "Company") refers to the following queries raised by the SGX-ST on 10 March 2023 and would like to provide additional information in relation to the Company's full year results for the financial year ended 31 December 2022 ("FY2022"), as follows:

SGX-ST's Query 1:

 

Please disclose:

 

(i) the nature of the non-current receivables; and

 

Company's response to Query 1(i):

The non-current receivables of US$54,000 are deposits for electricity and water for the Group's subsidiary in the United States.

(ii) the Board's assessment of the recoverability of the non-current other receivables and prepayments.

Company's response to Query 1(ii):

 

The Board is of the opinion that the non-current other receivables and prepayments are recoverable.

SGX-ST's Query 2:

 

It is disclosed on page 17 of the unaudited financial statements that the impairment charge in 2H FY2022 and FY2022 was attributed to a goodwill impairment of US$5.2 million, which is non-cash in nature, related to the performance of the Group's US subsidiary. The requirement to recognise this charge has arisen due to the sustained loss making position of the Group's US subsidiary. In this regard, please disclose the following information:

 

(i) how the amount of impairment was determined;

 

(ii) whether any valuation was conducted; the value placed on the relevant assets; the basis and the date of such valuation;

 

 

Company's response to Queries 2(i) & 2(ii):

 

The Group has goodwill of US$5.2 million allocated to the United States subsidiary cash-generating units ("CGUs") as at 31 December 2022.

 

These CGUs are tested for impairment annually. Management applies the value in use method to determine the recoverable amount of each CGU. Any shortfall of the recoverable amounts against the carrying amounts are recognised as an impairment loss. The recoverable amount is determined based on estimates of forecasted revenue, growth rates, profit margins and discount rates.

 

(iii) the Board's confirmation as to whether it is satisfied with the reasonableness of the methodologies used to determine amount of impairment.

Company's response to Query 2(iii):

The Board is satisfied with the reasonableness of the methodologies used to determine the amount of impairment.

 

 

SGX-ST's Query 3:

 

Please explain why no interest income was recorded during the financial period ended 31 December 2022 when the Company has significant cash and bank balance amounting to US$9,244,000.

Company's response to Query 3:

 

The majority of the Group's cash and cash balances are in the United Kingdom bearing either zero or very low interest, resulting in interest income of less than US$100 which is below the reporting threshold.

 

 

SGX-ST's Query 4:

 

Please provide information on the Group's inventory turnover days. Company's response to Query 4:

 

The Group's inventory turnover days are as follows:

 

 

FY2022

FY2021

Inventory turnover days

150 days

145 days

 

 

SGX-ST's Query 5:

 

Please disclose a breakdown of other payables amounting to US$3,109,000 and US$4,447,000 as at 31 December 2022 and 31 December 2021 respectively. For other payables, please disclose the nature of these other payables and whether the counterparties are related parties.

 

 

Company's response to Query 5:

 

The nature of other payables are as follows:

 

 

FY2022

FY2021

 

US$'000

US$'000

Accrued operating expenses

1,574

2,409

Provision for warranty

148

235

Customers advances received

781

1,085

GST/VAT payables

84

177

Other creditors

522

693

3,109

4,599

 

No counterparties are related parties.

 

 

SGX-ST's Query 6:

 

Please confirm if there are any outstanding convertibles and if yes, the number shares that may be issued on conversion of the outstanding convertibles.

 

Company's response to Query 6:

 

There are no outstanding convertibles.

BY ORDER OF THE BOARD

 

 

Gordon Blaikie

Interim Chief Executive Officer

 

 

14 March 2023

 

 

For further information, please contact:

 

Global Invacom Group Limited

www.globalinvacom.com

Gordon Blaikie, Interim Chief Executive Officer

via Vigo Consulting

 

Strand Hanson Limited (Nominated Adviser and Broker)

www.strandhanson.co.uk

James Harris / Richard Johnson / David Asquith

Tel: +44 20 7409 3494

 

Vigo Consulting (UK Media & Investor Relations)

www.vigoconsulting.com

Jeremy Garcia / Fiona Hetherington / Kendall Hill

Tel: +44 20 7390 0238

ginv@vigoconsulting.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEANDLFEADEEA
Date   Source Headline
4th Aug 20157:01 amRNSNotice of EGM
29th Jul 20157:00 amRNSPerformance Guidance
24th Jul 201510:38 amRNSChange of Address of Share Registrar
22nd Jun 20151:45 pmRNSGrant of Options
22nd Jun 201512:30 pmRNSTransaction in Own Shares
19th Jun 201510:30 amRNSNotice of Sale of Treasury Shares
5th Jun 201510:30 amRNSTransaction in Own Shares
3rd Jun 201510:30 amRNSTransaction in Own Shares
2nd Jun 20157:00 amRNSAcquisition of Skyware Global
29th Apr 201510:45 amRNSResult of AGM
13th Apr 20157:00 amRNSAnnual Report and Accounts
26th Feb 20157:01 amRNSFull Year statement for year end 31 December 2014
23rd Jan 20159:30 amRNSTransaction in Own Shares
22nd Jan 20159:30 amRNSTransaction in Own Shares
21st Jan 201510:26 amRNSTransaction in Own Shares
19th Jan 20159:45 amRNSTransaction in Own Shares
16th Jan 20159:30 amRNSTransaction in Own Shares
15th Jan 20159:30 amRNSTransaction in Own Shares
14th Jan 201510:40 amRNSTransaction in Own Shares
13th Jan 20159:27 amRNSTransaction in Own Shares
12th Jan 20159:30 amRNSTransaction in Own Shares
9th Jan 201510:35 amRNSTransaction in Own Shares
11th Nov 20147:08 amRNSGlobal Invacom completes acquisition
14th Oct 201410:45 amRNSTransaction in Own Shares
13th Oct 20149:30 amRNSTransaction in Own Shares
9th Oct 201411:17 amRNSTransaction in Own Shares
8th Oct 201411:00 amRNSTransaction in Own Shares
24th Sep 20147:00 amRNSGlobal Invacom acquires OnePath Networks
15th Sep 201411:42 amRNSTransaction in Own Shares
10th Sep 201410:32 amRNSTransaction in Own Shares
9th Sep 201411:30 amRNSTransaction in Own Shares
8th Sep 201410:59 amRNSTransaction in Own Shares
5th Sep 201411:20 amRNSTransaction in Own Shares
4th Sep 201412:36 pmRNSTransaction in Own Shares
3rd Sep 201410:51 amRNSTransaction in Own Shares
3rd Sep 20147:00 amRNSTransaction in Own Shares
14th Aug 20147:00 amRNSInterim Results
2nd Jul 20147:00 amRNSAdmission to Trading on AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.